Artboard 11

Marinomed suspends offer period of the current IPO

Marinomed Biotech AG (“Marinomed” or the “company”) received positive feedback from numerous domestic and international investors during the roadshow of its ongoing offering. While firm investor participation to buy new shares was obtained, the current adverse market conditions with high volatility did not allow to fully achieve the targeted offer volume. Marinomed therefore suspends the current offer period (which runs until today, 5 pm CET). Subject to the market environment, the company plans to resume the offer period presumably at the beginning of 2019.

The suspension of the offer period also relates to the qualifying public offering in accordance with the terms and conditions of the convertible bonds issued by Marinomed Biotech AG in 2017, which are traded on the Third Market of the Vienna Stock Exchange.

About Marinomed Biotech AG

Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at www.marinomed.com.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.